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Abstract 
 
Von Willebrand Factor (VWF) is a key component for maintenance of normal 
haemostasis, acting as the carrier protein of the coagulant Factor VIII and mediating 
platelet adhesion at sites of vascular injury. There is ample evidence that VWF 
glycan moieties are crucial determinants of its expression and function. Of particular 
clinical interest, ABH antigens influence VWF plasma levels according to the blood 
group of individuals, although the molecular mechanism underlying this phenomenon 
remains incompletely understood.  
This manuscript reports analyses of the human plasma VWF N-glycan population 
using advanced mass spectrometry. Glycomics analyses revealed about 100 distinct 
N-glycan compositions and identified a variety of structural features including 
lactosaminic extensions, ABH antigens, sulfated antennae as well as bisecting and 
terminal GlcNAc residues. We estimate that some 300 N-glycan structures are 
carried by human VWF.  
Glycoproteomics analyses mapped ten of the consensus sites known to carry N-
glycans. Glycan populations were found to be distinct although many structural 
features were shared across all sites. Notably, the H antigen is not restricted to 
particular N-glycosylation sites. Also, the N2635 site, previously designated as 
unoccupied, was found to be highly glycosylated. The delineation of such varied 
glycan populations in conjunction with current models explaining VWF activity will 
facilitate research aimed at providing a better understanding of the influence of 
glycosylation on VWF function. 
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Introduction 
 
Von Willebrand Factor (VWF) is a very large multimeric plasma glycoprotein 
expressed by vascular endothelial cells and megakaryocytes. VWF is a key 
component for maintenance of normal haemostasis, mediating two essential 
functions. Firstly, it supports platelet adhesion to damaged surfaces at sites of 
vascular injury by interacting with both the exposed sub-endothelial matrix proteins 
and the platelet glycoprotein complexes GpIbα and GpIIbIIIa [1]. Secondly, it acts as 
the carrier molecule for the pro-coagulant factor VIII, increasing its half-life in blood 
from 2 to 12 hours in humans and protecting it from activation by Factor Xa and 
inactivation by protein C [2, 3]. During its biosynthesis VWF undergoes extensive 
post-translational modification including pro-peptide cleavage, multimerisation and 
glycosylation, leading to a wide range of very large and structurally complex 
disulphide-linked multimeric structures of 0.5x106 to over 2x107 Da. The mature VWF 
monomer macrostructure is conventionally organised in four groups of homologous 
repeating domains named A, B, C and D joined together by unstructured linkers. A 
number of functional domains have been characterized along the 2813 amino acid 
VWF sequence, being involved either in its intrinsic properties (dimerisation, 
multimerisation, cleavage by the ADAMTS-13 metalloprotease; [4]) or in its 
interaction with partner proteins such as Factor VIII [5], collagens [6, 7], platelet 
GpIbα and GpIIbIIIa [8, 9], P-selectin [10] or heparin [11].  
The initial determination of the VWF amino acid sequence by Titani and collaborators 
[12] highlighted the presence of twelve N-glycosylation consensus sequons N-X-S/T 
(amino acids N857, N1231, N1515, N1574, N2223, N2290, N2357, N2400, N2546, N2585, N2635 and 
N2790). All but one of these sites (N2635) was reported to be occupied with N-glycans. 
An additional rare sequon, N-X-C (N1147), was also found to be glycosylated. Early 
studies of the VWF N-glycan population led to the characterisation of about twenty-
five N-glycan structures [13-15]. Complex type bi-antennary structures were shown to 
constitute about 80% of the glycans identified, accompanied by tri- and tetra-
antennary analogues as well as a minority of high mannose type N-glycans. Some 
structural features such as core fucosylation, antennae sialylation, and presence of 
lactosaminic elongations and of bisecting GlcNAc residues characterised the overall 
population. Interestingly, about 13% of the VWF N-glycans were shown to carry ABH 
blood group epitopes, an uncommon feature for a secreted glycoprotein.  
Most of the VWF N-glycosylation consensus sequons are located in the vicinity of, or 
within, a functional site and it is therefore not surprising that VWF glycan content 
affects its properties and functions such as secretion and dimerisation [16, 17], 
multimerisation [18] and half-life in blood [19]. One of the most striking effects, is the 
correlation between ABO blood group and VWF plasma level; Significant differences 
between all ABO groups have been demonstrated by many studies, demonstrating 
the highest levels for blood group AB individuals, followed by group A, group B and 
lowest levels for group O individuals, i.e. AB > A ≥ B > O [20, 21]. The mechanism by 
which ABH antigens affect VWF plasma level remains unclear, although most 
evidence points to an effect on VWF clearance. ABH antigens also alter VWF 
susceptibility to proteolysis by ADAMTS-13, a specific protease regulating VWF 
multimeric size, with a cleavage rate in the rank order O > B ≥ A > AB [22]. VWF 
sialylation has also been shown to specifically enhance susceptibility to ADAMTS-13 
proteolysis [23] whilst protecting it against cleavage by other serine and cysteine 
proteases such as plasmin, trypsin and chymotrypsin [24]. Interestingly, a recent 
study by McGrath and collaborators additionally demonstrated that desialylation 
abolishes the ABH effect on ADAMTS-13 cleavage rate, i.e. asialo-O-VWF and 
asialo-AB-VWF are cleaved at identical rates by ADAMTS-13 [23]. 
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Although substantial evidence shows a significant influence of the VWF glycan 
content on its biology and functions, most of the underlying molecular mechanisms 
remain poorly understood, in part because the knowledge of its glycans is still vastly 
incomplete. Only a portion of the VWF glycan repertoire has been rigorously defined 
and almost nothing is known regarding sialylation and potential further modifications. 
In addition, until now, nothing has been known concerning the specificity of 
glycosylation at each of the consensus sites. In this paper, we describe our structural 
definition of the VWF N-glycan repertoire using advanced mass spectrometric 
techniques. We report structural features which had not been addressed previously, 
such as sulfation, sialylation status and the presence of terminal non bisecting 
GlcNAc residues. Importantly, we show that ABH blood group-substituted glycans 
are distributed throughout the VWF molecule.  
 
Materials and methods 
 
Von Willebrand Factor 
Plasma-derived VWF was purified from Haemate P (ZLB, Behring, Germany) using a 
combination of gel filtration and heparin-Sepharose affinity chromatography. Briefly, 
Haemate P was gel filtered through a Hi-Prep Sephacryl S-400 HR gel filtration 
column (GE Healthcare, Little Chalfont, UK) using 20 mM Tris-HCl, 100 mM NaCl, 
pH 7.4. VWF-containing fractions were pooled and passed over a SK-16 
chromatography column packed with 30 ml of heparin-sepharose 6 fast flow (GE 
Healthcare). The column was eluted with 20 mM Tris-HCl, 300 mM NaCl, pH 7.4 and 
the resulting fraction was dialyzed into 50 mM ammonium bicarbonate, pH 7.4 prior 
to lyophilisation.  
 
General chemicals and reagents 
Ammonium hydrogen carbonate (NH4HCO3), sodium chloride (NaCl), iodoacetic acid 
(IAA), dithiothreitol (DTT), α-cyano-4-hydroxycinnamic acid, and hexanes were 
purchased from Sigma-Aldrich Corporation (Poole, Dorset, UK). Glacial acetic acid, 
acetonitrile (ACN), ammonia (NH3), chloroform (CHCl3), dimethylsulfoxide (DMSO), 
methanol (MeOH), propan-1-ol, sodium hydroxide pellets (NaOH) and trifluoroacetic 
acid (TFA) were from Romil (Waterbeach, Cambridgshire, UK). Gentisic acid (2,5 re- 
dihydroxybenzoic acid) was from Fluka (Poole, Dorset, UK). Methyl iodide (ICH3) was 
obtained from Alpha Aesar (Morecambe, Lancashire, UK). Snakeskin® dialysis tubing 
(cut-off 7 kDa) was from Pierce (Tattenhall, Cheshire, UK). 
Tris(hydroxymethyl)aminomethane was from Fisher (Loughborough, Leicestershire, 
UK). 3,4-diaminobenzophenone (DABP) was from Acros Organics, NJ). Argon and 
nitrogen gases were supplied by BOC (Guilford, Surrey, UK). All aqueous solutions 
were prepared using distilled/deionised (Milli-Q) water. 
 
Carboxymethylation 
Lyophilized VWF aliquots (typically 100 µg) were dissolved in 200 µl of 2 mg/ml 
dithiothreitol in degassed 0.6 M Tris, pH 8.5 buffer and reduction was carried out by 
incubation for 60 min at 37°C. The same volume of 60 mg/ml iodoacetic acid in 
degassed 0.6 M Tris, pH 8.5 buffer was then added and carboxymethylation was 
performed by incubation for 2 h at room temperature. The reaction was terminated by 
dialyzing samples against 50 mM ammonium bicarbonate, pH 7.4 buffer for 36 h at 
4°C. After dialysis, the VWF samples were lyophilized.  
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Tryptic and PNGase F digestions 
For glycomics analyses, reduced-carboxymethylated VWF was incubated with L-1-
tosylamido-2-phenylethyl chloromethyl ketone (TPCK) treated bovine pancreas 
trypsin (EC 3.4.21.4; Sigma, Poole, UK) at a 1:50 ratio (w/w) in 50 mM ammonium 
bicarbonate, pH 8.4 buffer, for 12 h at 37°C. For glycoproteomic analyses, reduced-
carboxymethylated VWF was digested using Sequencing Grade Modified Trypsin 
(Promega) at a 1:50 ratio (w/w) in a 50 mM ammonium bicarbonate, pH 8.4 buffer, 
for 2 to 14 h at 37°C. The digestion was terminated by addition of one drop of glacial 
acetic acid and the sample was immediately purified on a reverse-phase C18 Sep-
Pak cartridge (Waters Corp., Milford, MA, USA) with the propan-1-ol / 5% acetic acid 
method. The C18 cartridge was conditioned successively with methanol, 5% acetic 
acid, propan-1-ol, and 5% acetic acid. The tryptic digest was loaded onto the 
cartridge and washed with 20 ml of 5% acetic acid. VWF peptides and glycopeptides 
were eluted sequentially with each 20%, 40% and 100% (v/v) propan-1-ol in water. 
20% and 40% propan-1-ol fractions were pooled and lyophilized. For the PNGase F 
digestion, the VWF tryptic digest was suspended in 50 mM ammonium bicarbonate, 
pH 8.4, and digested with three units of the enzyme for 24 h at 37°C. The released 
N-glycans were extracted and purified from the sample using a Sep-Pak C18 cartridge 
with the propan-1-ol / 5% acetic acid method as before, the N-glycans being eluted 
using 5 ml of 5% (v:v) acetic acid. The volume of this fraction was reduced on a 
Savant Speed-Vac and purified N-glycans were finally lyophilised.  
 
Digestion by endo β-galactosidase 
Polylactosaminic elongations carried by VWF N-glycans were digested using a 
recombinant endo β-galactosidase from Escherichia freundii (EC 3.2.1.103, 
Seikagaku Corporation). The sample was dissolved in 50 mM ammonium acetate, 
pH 5.5 buffer. 25 mU of the endo β-galactosidase were added and the sample was 
incubated for 18 h at 37°C. Another aliquot of the enzyme were added, and the 
sample was again incubated for 18 h at 37°C. Glycans were purified using a Sep-
pak® C18 cartridge with the propan-1-ol / 5% acetic acid method prior to lyophilisation. 
 
Galactosylation with β1-4 galactosyltransferase 
Purified N-glycans were dissolved in 100 μl of a 50 mM MOPS, 20 mM MnCl2, pH 7.4 
buffer containing 1 mg/ml of UDP-galactose. 1 mU of β1-4 galactosyltransferase from 
bovine milk (EC 2.4.1.90, Merck, Middlesex, UK) was added and the sample was 
incubated for 24 h at 37°C. Another aliquot of the enzyme solution was then added 
and the sample was again incubated 24 h at 37°C. After reaction, glycans were 
purified using a Sep-pak® C18 cartridge with the propan-1-ol / 5% acetic acid method 
prior to lyophilisation. 
 
Digestion by neuraminidase 
Desialylation of released glycans or glycopeptides was achieved using a recombinant 
neuraminidase from Vibrio cholerae (EC 3.2.1.18, Sigma). The sample was dissolved 
in 50 mM ammonium acetate, pH 5.8 buffer. 25 mU of the recombinant 
neuraminidase were added and the sample was incubated for 18 h at 37°C. Another 
aliquot of the enzyme was added, and the sample was again incubated for 18 h at 
37°C. Glycans were then purified using a Sep-pak® C18 cartridge using the propan-1-
ol / 5% acetic acid method prior to lyophilisation. 
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Chemical derivatisation 
VWF N-glycans were explored using a technique adapted from a recently developed 
strategy published by Khoo and collaborators [25]. Lyophilised and purified VWF N-
glycans were dissolved in about 100 µl of the NaOH/DMSO slurry and 100 µl of 
methyl iodide. The samples were gently mixed and incubated for 3 hours at 4°C. The 
permethylation was then stopped by addition of a few drops of ice-cold water, 
followed by pH neutralisation to around pH 6.5 using a 5% (v:v) acetic acid solution. 
Glycans were then cleaned-up using a Sep-Pak® C18 cartridge with the acetonitrile / 
water protocol. The reverse-phase was conditioned successively with methanol, 
water, acetonitrile and water. The sample was dissolved in 1:1 (v:v) methanol/water 
and loaded onto the cartridge. Hydrophilic salts and contaminants were washed off 
by passing 10 ml of water, then 5 ml of a 2.5% (v:v)  acetonitrile solution. Glycans 
were then sequentially eluted (according to their size and composition) using 5 ml of 
10%, 25%, 50% and 75% (v:v) aqueous acetonitrile solution. Organic solvent from 
each fraction was removed on a Savant Speed-Vac and samples were lyophilised.  
 
Linkage analysis 
Permethylated N-glycans were hydrolyzed to partially methylated monosaccharides 
by incubation in 2 M trifluoroacetic acid at 121°C for 2 h. Samples were dried under a 
stream of nitrogen. Reduction of the monosaccharides and tagging of their carbon 1 
was achieved by incubation for 2 h at room temperature in a 10 mg/ml NaBD4 in 2 M 
NH4OH solution. The reaction was terminated by the addition of five drops of glacial 
acetic acid and samples were dried under a stream of nitrogen. Excess borates were 
removed by co-evaporation with a 10% (v:v) acetic acid in methanol solution followed 
by drying under a stream of nitrogen. Samples were acetylated by incubation in 
acetic anhydride for 1 h at 100°C and then dried under a stream of nitrogen. The 
resulting products were extracted with chloroform in the same way as permethylated 
samples. The chloroform layer was dried down and the partially methylated alditol 
acetates (PMAA) were dissolved in hexanes prior to gas chromatography (GC)-MS 
analyses, performed on a Perkin Elmer Clarus 500 GC-MS (Perkin Elmer 
Instruments, Shelton, USA) machine fitted with an RTX-5MS column (30 m long, 0.25 
mm internal diameter, Thames Restek UK Limited, Saunderton, Bucks, UK). The 
PMAA were injected at 60°C then the temperature was increased at a rate of 
8°C/min to a temperature of 300°C. Data were acquired and processed using GC-MS 
Turbomass v4.5.0 Instrument Control software. 
 
Affinity chromatography on Ulex europaeus agglutinin (UEA-I) lectin 
The Ulex europaeus agglutinin I (UEA-I) has been reported to bind efficiently and 
specifically to fucosylated structures and especially to blood group H containing type 
2 chain epitopes (Fuc α1→2 Gal β1→4 GlcNAc) [26]. 2 ml of agarose bound Ulex 
europaeus agglutinin I (EY Lab, CA, USA) was packed in a 2 ml glass column and 
equilibrated using 10 column volumes of 10 mM sodium phosphate, 150 mM NaCl, 
pH 7.4 buffer. The flow rate was set up at 0.1 ml/min for the whole experiment. VWF 
desialylated glycopeptides aliquots (obtained from treatment by neuraminidase, as 
described above) were dissolved in 100 µl of PBS buffer and loaded onto the 
column. The column was washed by 10 column volumes and the subsequent 
unbound fraction was collected. Bound glycopeptides were then eluted using the 
same buffer containing 500 mM of L-fucose. Both bound and unbound fractions were 
immediately purified using a Sep-pak® C18 cartridge with the propan-1-ol / 5% acetic 
acid method to remove the salt and sugar excess prior to LC separation and/or MS 
analyses. 
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Nano-LC separation and spotting 
VWF tryptic digests were analysed by off-line liquid chromatography / matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (off-line LC-MALDI-TOF 
MS). Peptides and glycopeptides were separated using an Ultimate 3000 LC system 
(Dionex, Sunnyvale, CA), fitted with a analytical Pepmap C18 nanocapillary column 
(15 cm length, 75 mm internal diameter; Dionex). The flow rate was set up at 0.3 
µl/min. The sample, diluted in 0.1% (v:v) TFA, was loaded onto the column. 
Sequential elution was carried out using solvent A (0.1% (v:v) TFA in 2% (v:v) 
acetonitrile and solvent B (0.1% (v:v) TFA in 90% (v:v) acetonitrile), with a gradient of 
0 to 60% solvent B (0 to 36 or 60 min long). The Ultimate 3000 LC system was 
connected to a Probot MALDI Spotter (LC-Packings). Eluting fractions (0.15 µl) were 
mixed with an equal volume of α-cyano-hydroxy cinnamic acid matrix (3 mg/ml in 
50/50 (v:v) 0.1% TFA / acetonitrile), spotted onto a metal MALDI-TOF/TOF target 
plate and left to dry at room temperature prior to MS analyses. 
 
Matrix assisted laser desorption ionisation – Time of flight (MALDI-TOF) MS 
analyses 
Derivatised VWF N-glycans were dissolved in 20 µl of 1:1 (v:v) methanol:water or 
VWF peptides were dissolved in 50 µl of 0.1% (v:v) TFA. 1 µl of sample was mixed 
with 1 µl of the matrix (for glycans in positive ion mode, 10 mg/ml of 2,5-
dihydroxybenzoic acid in 50:50 (v:v) methanol:water; for glycans in negative ion 
mode, 10 mg/ml 3,4-diaminobenzophenone in 50:50 (v:v) acetonitrile/0.1% (v:v) TFA; 
for peptides, 5 mg/ml in 50/50 (v:v) 0.1% TFA / acetonitrile). 1 µl of the subsequent 
mixture was spotted onto a 100-well sample plate and dried under vacuum. MALDI-
MS analysis was performed using a Voyager DE-STR™ (Applied Biosystems, 
Warrington, Cheshire, UK) mass spectrometer in the reflectron mode with delayed 
extraction The instrument was calibrated externally using the Calmix 4700 calibration 
standard, containing des-Arg1-Bradykinin (Molecular weight 904.46 Da), angiotensin 
I (Mw 1296.68 Da), human [Glu1]-fibrinopeptide B (Mw 1570.67 Da), ACTH fragment 
1-17 (Mw 2093.08 Da), ACTH fragment 18-39 (Mw 2465.19 Da), and ACTH fragment 
7-38 (Mw 3657.92 Da). Data were acquired using Voyager 5 Instrument Control 
Software and were processed using Data Explorer MS processing software. 
 
Matrix assisted laser desorption ionisation – Time of flight/Time of flight 
(MALDI-TOF/TOF) MS/MS analyses 
Sample-matrix mixtures were prepared as before, spotted onto a MALDI TOF/TOF 
sample plate and dried under vacuum. MS/MS data were acquired using a 4800 
MALDI TOF/TOF™ (Applied Biosystems, Damstadt, Germany) mass spectrometer. 
The collision energy was set to 1 kV and argon was used as collision gas. The 
instrument was calibrated using [Glu1]-fibrinopeptide B human (Sigma-Aldrich, UK) 
as external calibrant for the MS/MS mode and the 4700 calibration standard, calmix, 
was used as the external calibrant for the MS mode. Data were acquired using 4000 
Series Explorer Instrument Control Software and were processed using Data 
Explorer MS processing software. 
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Results 
 
Human plasma VWF was purified from Haemate P, a commercial plasma 
concentrate manufactured for patients with haemophilia or von Willebrand disease 
(VWD), using size exclusion and affinity chromatography techniques. The strategy 
undertaken to achieve VWF glycomics and site-by-site glycosylation analyses is 
summarised in Figure 1. For glycomics analyses, VWF was reduced, 
carboxymethylated and digested with trypsin. N-glycans were released by PNGase F 
digestion, purified using a reverse phase C18 cartridge then permethylated prior to 
MALDI-TOF and TOF/TOF analyses. Glycomics experiments were supplemented by 
enzymatic treatment (neuraminidase, β-galactosyltransferase, endo-β-
galactosidase). For glycoproteomics analyses, VWF tryptic digests were desialylated 
using sialidase A and, in some experiments, enriched by UEA-I affinity 
chromatography, prior to analyses using an off-line C18 nano-LC MALDI-TOF/TOF 
system.  
Data from the permethylated VWF N-glycans MALDI-TOF MS analysis are shown in 
Figure 2 and Supplementary Table 1. For glycomics data, all molecular ions are 
[M+Na]+ and panels are normalised to 100% intensity unless otherwise stated. 
Structural assignments are based on monosaccharide composition (MALDI-TOF MS, 
GC-MS), fragmentation analyses (MS/MS), enzymatic digest sequencing and 
knowledge of the glycan biosynthetic pathways. Bearing in mind that a single 
molecular ion is often composed of several isoforms (as exemplified in Figure 3), the 
proposed structures either correspond to the most abundant isoform or are 
representative of a group carrying a common structural motif. The profile is 
dominated by sialylated and fucosylated bi-antennary structures (m/z 2431.2, 2605.3, 
2779.4 and 2966.5). A remarkably high variety of tri- and tetra-antennary N-glycans 
are observed in smaller abundance (m/z 3402.7, 3793.9, 3922.9, 4314.1, etc). Minor 
signals consistent with high mannose structures Man5 to Man8 are also detected (m/z 
1579.8, 1783.9, 1988.0 and 2192.1).  
 
N-glycan fucosylation 
A high proportion of molecular ions are consistent with complex type multi-
fucosylated N-glycans suggesting fucosylation of both core and antennae (m/z 
2418.2, 3041.5, 4025.9 etc.), in accordance with previous publications reporting the 
occurrence of ABH blood group antigens on VWF N-glycans [15]. The presence of 
fucose residues was confirmed by gas chromatography (GC)-MS as shown in Table 
1 and Supplementary Figure 1. Terminal fucose residues were firmly identified 
(retention time 17.00 min; EI spectrum in Supplementary Figure 2.A) and core 
fucosylation was revealed by the detection of 4,6-linked GlcNAc residues (retention 
time 24.47 min; Supplementary Figure 2.B). Core fucosylation was also 
demonstrated by CID fragmentation, as shown in Figures 3.A & 3.B, MS/MS spectra 
of the m/z 2633.3 and 3054.5 molecular ions providing fragment ions diagnostic of 
core-fucosylated structures (m/z 474, 2212 and 2604).  
Antennae fucosylation was demonstrated via the detection of 2-linked galactose 
residues amongst the PMAA population (retention time = 19.88 min; Supplementary 
Figure 2.C). MS/MS analyses confirmed the presence of H antigens through the 
detection of diagnostic fragment ions m/z 433 and 660 (Fuc1Hex1 and 
Fuc1Hex1HexNAc1, respectively; Figure 3.A). A diagnostic fragment ion at m/z 905 
also demonstrates blood group A antigens within this sub-population of molecular 
ions. In the same way, blood group B antigens were observed on other VWF N-
glycans via diagnostic fragment ions at m/z 619 and 864 (Fuc1Hex2 and 
Fuc1Hex2HexNAc1, respectively; data not shown). Finally, no evidence for Lewis or 
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sialyl Lewis epitopes was found, suggesting that on VWF N-glycans, antennae 
fucosylation is restricted to the position 2 of galactose residues. 
 
Presence of lactosamine extensions 
Some high mass molecular ions suggest the presence of lacNAc extensions because 
the total of lacNAc units is higher than the four needed for a tetra-antennary glycan 
(Figure 2.D; m/z 4314.1, 4488.2 and 4675.2). In addition, CID fragmentation of many 
lower mass molecular ions such as m/z 3054.5 yielded fragment ions characteristic 
of lacNAc elongations (Figure 3.B; m/z 1296, 1781 and 2142), highlighting that this 
feature is also present in bi- and tri-antennary structures. The presence of lacNAc 
elongations was also assessed by digesting native VWF N-glycans with an endo β-
galactosidase prior to permethylation and MS analyses. The low mass region of the 
subsequent MS spectrum (Supplementary Figure 3.A) contains a variety of molecular 
ions consistent with lactosaminic elongations, with or without ABH blood group 
epitopes or a sialic acid residue (m/z 722.4, 896.5, 1083.6, 1100.6, 1141.6 and 
1171.6). The structure of these elongations was confirmed by MS/MS analysis as 
shown in Supplementary Figure 3.B & 3.C. 
 
Presence of both bisecting and terminal GlcNAc residues 
A number of glycan compositions determined by MS analysis suggest the presence 
of HexNAc residues additional to those present in the N-glycan core plus the lacNAc 
building blocks of the antennae (Figure 2; m/z 2315.2, 2663.3, 3211.6, etc.). These 
extra HexNAcs could theoretically be attributed to GalNAc residues forming the A 
antigen in the periphery, to Sda epitopes (NeuAc (GalNAc ) Gal GlcNAc)α2,3 β1-4 β1-4 , to 
bisecting GlcNAc residues or to non-galactosylated antennae.  
The A antigen was characterised by MS/MS analysis of a number of molecular ions 
of this sub-population, as shown in Figure 3.A. Global fragmentation data suggest 
that 15-20 % of the extra HexNAcs are GalNAc involved as an A antigen. The Sda 
epitope was firmly ruled out by the overall MS/MS data which showed no evidence 
for the predicted diagnostic fragment ion at m/z 1092 (NeuAc1Hex1HexNAc2). The 
nature of some of these HexNAc residues was then uncovered by GC-MS analyses, 
which revealed the presence of 3,4,6-linked mannose within the population of N-
glycan-derived PMAA (retention time = 21.43 min; Supplementary Figure 2.D). This 
residue is characteristic of bisected structures in which the 3,6-substituted β-Man is 
additionally substituted by the so-called bisecting GlcNAc in a β1-4 linkage. Finally, in 
order to confirm or exclude the presence of terminal non-bisected GlcNAc residues 
(non-galactosylated, or truncated antennae), native N-glycans were incubated with 
β1,4-galactosyltransferase in the presence of UDP-Gal. This enzyme catalyses the 
addition of a galactose residue to exposed GlcNAc residues, but, due to steric 
hindrance, does not have access to bisecting GlcNAc residues. The resulting MALDI-
TOF spectra of VWF permethylated N-glycans before and after incubation are shown 
in Supplementary Figure 4. Both spectra are normalised to fully capped N-glycans 
which cannot be further modified by the enzyme (m/z 2779.4 and 2792.4). Molecular 
ions consistent with fully galactosylated glycans (m/z 2070.0, 2244.1, 2417.2, 2431.2, 
2605.3 and 2693.5) are detected at higher intensity after treatment by β1,4-
galactosyltransferase whereas molecular ions consistent with non-fully 
galactosylated species decrease in intensity (m/z 2285.2 and 2850.5) after reaction, 
demonstrating that a portion of VWF N-glycans carry a terminal GlcNAc residue in a 
non-bisected terminal position. Such truncated antennae are particularly uncommon 
for blood glycoproteins, on which N-glycans tend to be fully processed.  
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Characterisation of sulphated epitopes 
An early report suggested that VWF carry a population of sulphated oligosaccharides 
[27]. The analysis of sulphated glycans by mass spectrometry is a difficult task, due 
to their general low abundance, the lability of sulphate groups and their poor 
ionisation with standard MS techniques. Nevertheless, an optimised sulphoglycomics 
methodology has been recently reported by Khoo and colleagues [25], and its 
adaptation to the VWF model allowed us to characterise a family of sulphated N-
glycans within the oligosaccharide population. The negative ion mode MALDI-TOF 
MS spectrum of the permethylated VWF N-glycans shown in Figure 4 exhibits a 
number of [M-H]- molecular ions consistent with mono-sulphated complex type 
structures (m/z 2647.3, 2821.4, 3008.5, 3096.5, 3457.7, 3631.8 and 3818.9). These 
N-glycans are broadly consistent with the positive ion mode profile established earlier 
(Figure 2.A). A related population of molecular ions was observed (m/z 2567.3, 
2741.4, 2928.5 and 3377.7), corresponding to glycans having lost sulphite (SO3) 
during or after the ionisation process. Negative ion mode MS/MS provided diagnostic 
fragment ions confirming the presence of sulphate groups. For instance, MS/MS of 
m/z 2647.3 yielded a sulphate ion at m/z 97 plus fragment ions consistent with a 
core-fucosylated bi-antennary mono-sialylated glycan carrying a sulphate on the 
lacNAc moiety of the sialylated antenna (Supplementary Figure 5; m/z 514.0, 700.3, 
1808.3 and 2272.0). 
 
Glycoproteomics analyses 
Following the characterisation of the VWF N-glycans, off-line LC-MS/MS 
glycoproteomics approaches were applied to the study of individual 
glycosylation sites. In silico tryptic digestion of mature VWF leads to 136 
tryptic peptides (Mw > 500 Da), among which 13 contain a single N-
glycosylation consensus sequon (Table 2; peptide-mass software; 
www.expasy.org). VWF was reduced, alkylated, trypsinized, and digested by 
neuraminidase (glycoproteomics data) or PNGase F (proteomics data) prior to 
analysis using a LC Pepmap C18 nanocapillary column connected to a Probot 
MALDI spotter and an Applied Biosystems 4800 MALDI TOF/TOF instrument. 
Automated interpretation of the proteomics data using the MASCOT search 
engine (www.matrixscience.com) confirmed a high purity level with only trace 
levels of contaminating peptides. Overall, about 60% of the VWF amino 
sequence (UniProtKB P04275) was successfully detected and sequenced, 
amongst which were ten tryptic peptides possessing a N-glycosylation 
consensus sequon (Table 2; Supplementary Figure 6). Glycoproteomics 
analyses were performed manually and led to the observation of various 
glycosylated forms of each of these ten peptides. With the exception of N1147, 
all these sites appeared to be fully occupied since their non-glycosylated 
counterparts were only detected after PNGase F digestion. Comprehensive 
data are shown for a single N-glycosylation site (Table 2; P4; 
I1509GEADFNR1516) while other individual site glycoproteomics data are 
summarised in Supplementary Tables 2 to 11.  
Three MALDI-TOF MS spectra obtained from LC fractions eluting between 20 and 22 
min are shown in Supplementary Figure 7. They exhibit a considerable number of 
[M+H]+ ions consistent with various glycosylated forms of the IGEADFNR peptide. 
MS analyses were complemented by CID fragmentation data such as that shown in 
Figure 5.A for m/z 3420.8. High mass fragment ions are consistent with loss of 
antennae (m/z 2528.0, 2909.4 and 3055.5) whilst the corresponding antennae 
fragments are observed in the low mass range (m/z 204.0, 366.1 and 512.2). The 
mid-mass range of the spectrum is highly informative and includes the m/z 921.3 
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fragment ion corresponding to the [M+H]+ ion of the peptide itself, accompanied by 
two major signals at m/z 904.3 and 1004.4 resulting from asparagine side-chain and 
GlcNAc cross-ring cleavages, respectively. The three further signals at m/z 1124.5, 
1270.5 and 1327.6 show the IGEADFNR peptide substituted by the N-glycan core 
monosaccharides. To compensate for the lack of information on the amino acid 
sequence, the VWF tryptic digest was additionally digested by PNGase F prior to 
nano-LC C18 injection. The observation of a molecular ion at m/z 922.3 consistent 
with the deglycosylated form of the peptide and its sequencing by CID fragmentation 
(Supplementary Figures 8.A and 8.B) confirmed the initial IGEADFNR sequence. The 
N1515 glycosylation site was thus demonstrated to carry a heterogeneous population 
of complex type bi-, tri- and tetra-antennary structures including multi-fucosylated 
(Supplementary Figure 7; m/z 2836.3, 3404.5, 3566.6) as well as “extra HexNAc” 
species (m/z 2747.3, 3404.5, 3769.5). The global description of the IGEADFNR 
glycopeptide population is shown in Supplementary Table 4.  
The importance of localising the blood group antigens along the VWF amino acid 
sequence led us to perform affinity chromatography using agarose bound fucose-
specific Ulex europaeus agglutinin (UEA-I) in order to obtain glycopeptide fractions 
enriched in the H antigen. UEA-I bound and unbound fractions were analysed on the 
same off-line nano-LC C18 MALDI-TOF/TOF system. The UEA-I enrichment step 
allowed the identification of many glycopeptides containing at least one H antigen, 
which were masked by more abundant alternative structures in the experiments 
described earlier. The MS spectrum shown in Figure 5.B was generated by summing 
the relevant consecutive spectra and therefore shows the overall population of H 
antigen containing N-glycans found at the N1515 glycosylation site. Mono- to tetra-
fucosylated N-glycans were observed, as well as a number of “extra HexNAc” and 
lactosamine extension containing species at relatively high abundance. The 
presence of H antigen at N1515 was finally confirmed by CID fragmentation, as shown 
in the exemplar MS/MS spectrum in Figure 5.C (m/z 512.2, 2837.3 and 3348.6).  
Unexpectedly, we found that, with the single exception of N1147, the H antigen is 
present at all detected VWF N-glycosylation sites. Based on the relative glycopeptide 
proportions established for all sites (Supplementary Tables 2 to 11), we evaluated 
the average number of complex type antennae and occurrence of antennae 
fucosylation per glycosylation site (Supplementary Table 12). Interestingly, the 
highest density of fucosylation was found at N2635 (15.9 % of the antennae being 
fucosylated), while most of the other sites carry N-glycans with about 10 % of 
fucosylated antennae. The three sites N857, N2290 and N2585 show a much lower 
degree of antennae fucosylation (1 to 3 %). In addition, the level of branching was 
found to be reasonably constant, with 2.2-2.3 antennae per glycan on average, with 
the exceptions of N857/N1147, carrying undersized structures (1.6-2.0 antennae per 
glycan) and of N1515/N1574, showing a greater proportion of bulky N-glycans (2.6 
antennae per glycan).  
 
 
Discussion  
The glycomics data presented in this report show the great complexity of the VWF N-
glycans as a population of approximately 300 distinct structures. Complex type N-
glycans, mainly bi-antennary, dominate the profile, although traces of high-mannose 
and truncated structures are also detected (Figure 2 and Supplementary Table 1). 
This profile is broadly in agreement with the study performed by Matsui and 
collaborators, although these workers only identified the most abundant N-glycans 
after desialylation, comprising about 25 structures [15]. Our analyses highlight a 
number of epitopes previously unknown on VWF and reveal the nature of low 
abundance components that were previously missed. The level of complexity of the 
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VWF N-glycan population is schematised in Figure 6.A and salient structural features 
are discussed in the next sections. 
Core fucosylation and capping of the terminal galactose, with either a α2,6 sialic acid 
or a α1,2 fucose residue, are predominant features. Human VWF N-glycans show a 
high sialylation status with about 50% of the overall complex type antennae being 
capped with a α2,6 neuraminic acid residue, while PMAA analyses revealed that about 
15% of the VWF N-glycan antennae are capped with a α1,2 fucose residue (Table 1). 
The presence of Lewis epitopes was ruled out by the absence of 3,4-linked GlcNAc 
residues in the linkage data and diagnostic fragment ions in tandem MS analyses. 
ABH antigens were found in similar abundance on all the families of complex type N-
glycans, suggesting that α1,2 fucosylation of galactose residues is not a structure-
specific process (Figure 2 and Table 1). Evidence for antennae containing both a 
neuraminic acid and a fucose residue was not found, in keeping with evidence 
indicating that fucosylation of sialylated antennae is restricted to α2,3 sialylation in 
mammals [28]. However, 35% of the total N-glycan compositions identified carry both 
sialic acid(s) and ABH antigen(s), but on distinct antennae. Finally, in contrast to the 
VWF O-linked glycans reported recently by our group, no evidence for di-sialic acid 
motifs has been found on N-glycans [29]. The α2,6 neuraminic acid residues identified 
here have been shown to have a protective effect against cleavage by serine and 
cysteine proteases but specifically enhance susceptibility to ADAMTS-13 proteolysis 
[23, 24]. As reported earlier, ADAMTS-13 activity is affected by ABH antigens and it 
is interesting to note that VWF desialylation abolishes the ABH blood group effect on 
the ADAMTS-13 proteolysis rate. Terminal α2,6 neuraminic residues are also 
recognised by the sialic acid binding Ig-like lectin family, the Siglecs [30, 31]. 
Although the individual affinity studies are still in progress, the Consortium for 
Functional Glycomics data suggest that Siglecs 2, 5, 7, 9 and 10 present a significant 
affinity for α2,6 NeuAc residues. Interestingly, Lenting and collaborators recently 
reported preliminary data suggesting that Siglecs 5, 7 and 9 are able to interact with 
VWF [32]. 
VWF has been reported once to carry sulfated N-glycans at the N1147 and/or N1231 
glycosylation sites, although until now, this early observation has not been 
corroborated with structural evidence [27]. Using a modern MS-based methodology, 
a pool of about 10 mono-sulfated N-glycans was firmly identified here (Figure 4), 
comprising bi- and tri-antennary structures containing at least one fucose and one 
NeuAc residue. From our MS/MS data, we conclude that sulfation occurs mainly on 
the sialylated LacNAc antennae (Supplementary Figure 5). Antennae sulfation may 
have important implications, in particular regarding recognition by specific glycan 
binding proteins. Human B cells expressing Siglec 2 have also been shown to 
interact with α2,6sialylated 6-sulfo-LacNAc epitopes [33]. Although the nature of the 
recognition remains unclear, VWF is known to interact with P-selectin and it is 
believed that this interaction is key to anchoring high molecular weight VWF to the 
surface of stimulated endothelial cells, thus facilitating their cleavage by ADAMTS-13 
[34]. Interaction between P-selectin and its major ligand (P-selectin glycoprotein 
ligand-1) is known to be mediated by both a sialyl LewisX epitope and an adjacent 
sulfated tyrosine residue. Although LewisX is absent on VWF N-glycans, sulfation of 
an antenna could conceivably, in conjunction with fucosylation of another nearby 
antenna, constitute a motif recognised by P-selectin.  
Our glycoproteomics data showed that N-glycans substituted with blood group H-
antigen are present on all but one of the observed glycosylation sites although its 
abundance is not uniform as represented in Figure 6.B. Glycans of the N-terminal 
domain (N857 and N1147) lack significant antennae fucosylation. N2290 and N2585 are 
rather poorly fucosylated relative to other sites, of which about 10% of the antennae 
are substituted with a α1,2 fucose (Supplementary Table 12). The most heavily 
fucosylated site is N2635, on which N-glycans carry the H antigen on about 16% of its 
antennae which is surprising and important, as this later glycosylation sequon was 
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until now reported as not glycosylated. The average number of antennae per glycans 
at individual sites appears to be reasonably constant, with 2.2-2.3 per glycan at most 
of the sites, with the exception of N857 and N1147 carrying smaller structures and of 
N1515 and N1574 whose N-glycans are somewhat more bulky (an average of 2.6 
antennae per glycan). These two glycosylation sites flank the ADAMTS-13 cleavage 
site, and our data suggest that this region is richer in the H-antigen than the rest of 
the molecule. Whether the H antigen density affects cleavage remains to be 
established. The trend of structural characteristics observed on individual 
glycosylation sites of desialylated VWF is summarised in Figure 6.B and detailed in 
Supplementary Tables 2 to 11.  
No satisfactory understanding of the correlation of ABH antigen expression to VWF 
cleavage by ADAMTS-13 has been provided to date. Possible explanations include 
steric hindrance affecting ADAMTS-13 cleavage, potential recognition of ABH 
antigens by ADAMTS-13, or an effect of the ABH status on the overall glycosylation. 
A recent report provided interesting evidence that desialylation of VWF abolishes the 
ABH blood group effect on the ADAMTS-13 cleavage rate, suggesting a relationship 
between the blood group status and the level of sialylation [22, 23]. It has also been 
suggested that blood group O-VWF could be more extensively sialylated than A- and 
B-VWF. It is conceivable that bulky A and B epitopes on one or more antennae 
sterically hinder sialic acid addition to other antennae on the same or nearby glycans. 
To address this issue, lectin purification strategies should be developed in the future 
to allow the enrichment of sialylated forms of blood group-substituted glycopeptides.  
To our knowledge, no other glycoprotein of this complexity has had its glycome and 
glycoproteome characterised in the depth achieved in the current study. This work 
highlights the ability of modern mass spectrometry-based techniques to provide 
highly detailed information concerning the diversity of glycoforms of extremely 
complex glycoproteins which should prove relevant for understanding their 
correspondingly complex functions. The well-known association between ABO blood 
group and plasma concentration of VWF is well documented and although most 
evidence suggests that it is mediated by an effect on clearance, the responsible 
receptors have not been fully identified. The Ashwell (asialoglycoprotein) receptor 
appears to make some contribution [35] but additional receptors remain to be 
identified and knowing that their ligands must exist among the glycan structures 
described in this report should aid their identification. Notably, a recent genome-wide 
association study identified the CLEC4M lectin locus as a novel determinant of VWF 
plasma level [36].  Proteolysis is known to be an important mechanism for regulation 
of VWF function and may also play a role in clearance. We have already 
demonstrated that N-linked glycans can modulate VWF interaction with the 
regulatory enzyme ADAMTS-13 [37] and that a complex balance between ABO 
antigen and sialic acid content determines the overall susceptibility of VWF to 
proteolytic degradation [23]. More recent data have indicated that the VWF interacts 
with the members of the galectin family via its carbohydrate moieties and that this 
has an effect on VWF function [38]. The significance of these interactions and their 
dependence on specific glycan structures at specific sites in the VWF molecule are 
not yet elucidated but will be facilitated by the data presented here.  Finally, VWF 
interacts with many other molecules, both before and after release from the 
endothelial cell. These include the numerous contents of the Weibel Palade bodies 
which are largely co-located by binding to VWF and we anticipate these too will be 
subject to regulation by the VWF glycans.  
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Table 1. GC-MS linkage analysis of partially methylated alditol acetates derived 
from VWF N-glycans.  
The elution time is in minutes and the relative abundance is normalised to 1.00, 
abundance of the major component, 2-linked mannose. 
Elution 
time 
Diagnostic  ions   Assignment 
Relative 
abundance 
% of the 
population 
17.00  102, 115, 118, 131, 162, 175  Terminal Fucose  0.15  5.2 
18.48  102, 118, 129, 145, 161, 162, 205  Terminal Mannose  trace  < 1.0 
18.76  102, 118, 129, 145, 161, 205  Terminal Galactose  0.29  10.2 
19,66  129, 130, 145, 161, 190, 205, 234  2‐linked Mannose  1.00  35.2 
19.88  129, 130, 145, 161, 190, 234  2‐linked Galactose  0.12  4.2 
19.92  118, 129, 161, 202, 203, 234, 277  3‐linked Mannose  0.08  2.8 
20.45  102, 118, 129, 162, 189, 233  6‐linked Galactose   0.38  13.3 
20.82  113, 130, 173 190, 233, 274  2,4‐linked Mannose  0.10  5.3 
21.20  129, 130, 189, 190, 233, 234  2,6‐linked Mannose  0.03  1.0 
21,38  101, 118, 129, 189, 202, 234, 305  3,6‐linked Mannose  0.33  11.6 
21.83  118, 129, 139, 202, 259, 333  3,4,6‐linked Mannose  0.05  1.7 
22,31  117, 129, 143, 145,159, 203, 273  Terminal GlcNAc 
22,31  117, 129, 143, 145,159, 203, 273  Terminal GalNAc 
0.03  1.0 
23.20  113, 117, 143, 159, 203, 233  4‐linked GlcNAc  0.32  11.2 
24.47  117, 127, 143, 159, 261, 301  4,6‐linked GlcNAc  0.05  1.7 
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Table 2. Properties of VWF N-glycosylation consensus sequons.   
The numbering of the VWF tryptic peptides that contain a N-glycosylation consensus 
sequon does not include the propeptide moieties and therefore begins at amino acid 
764.  
 
Peptide 
number 
Predicted N‐
glycosylated sites 
Tryptic peptide sequences  [M+H]+ Mapped 
P1  N857 W856NCTDHVCDATCSTIGMAHYLTFDGLK882 3176.3  √ 
P2  N1147
Y1146NSCAPACQVTCQHPEPLACPVQCVEGCHA
HCPPGK1181
4183.6  √ 
P3  N1231,  
V1212TLNPSDPEHCQICHCDVVNLTCEACQEPGG
VVPPTDAPVSPTTLYVEDISEPPLHDFYCS R1274
7198.2  No 
P4  N1515 I1509GEADFNR1516 921.4  √ 
P5  N1574 Y1570QGGNR1575 694.3  √ 
P6  N2223 H2219CDGNVSSCGDHPSEGCFCPPDK2241 2622.9  √ 
P7  N2290 V2289NCTTQPCPTAK2300 1378.6  √ 
P8  N2357 G2342LQPTLTNPGECRPNFTCACR2363    2452.1  √ 
P9  N2400
T2386QCCDEYECACNCVNSTVSCPLGYLASTATN
DCGCTTTTCLPDK2429   
5123.9  No 
P10  N2546 N2546VSCPQLEVPVCPSGFQLSCK2566    2409.1  √ 
P11  N2585 M2579EACMLNGTVIGPGK2593       1578.7  √ 
P12  N2635 E2633ENNTGECCGR2643 1327.5  √ 
P13  N2790 T2779EPMQVALHCTNGSVVYHEVLNAMECK2805 3119.4  No 
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Figure legends 
 
Figure 1. Overview of structural glycomics and glycoproteomics strategies 
employed in this study. * = β1-4 galactosyltransferase, endo β-galactosidase or 
neuraminidase 
 
Figure 2. MALDI-TOF-MS profile of the permethylated N-linked glycans from 
VWF 
The full scale spectrum (A) and subsequent magnified portions (B to D; m/z 1500-
2500, 2500-3500 and 3500-5000, respectively) show the high complexity of the VWF 
glycan population. Structural assignments were based on compositions assigned 
from molecular weights, complemented by MS/MS information and the results of 
glycosidase digests. As discussed in the text, individual signals often correspond to a 
number of isomers, but for clarity only the most abundant isoform or one 
representative of a family carrying a common structural motif is represented. All 
molecular ions are [M+Na]+ and panels are normalised to 100% intensity. Structural 
assignments are based on monosaccharide composition, fragmentation analyses, 
and knowledge of the glycan biosynthetic pathways. The sugar symbols are those 
employed by the Consortium for Functional Glycomics 
(www.functionalglycomics.org). 
 
Figure 3. MALDI-TOF-TOF fragment ion spectra of the parent ions at m/z 2663 
and 3054.  
These MS/MS spectra obtained after collisional activation reveal diagnostic 
fragmentation patterns consistent with the structures shown in the inset. The 
horizontal arrows depict the loss of the designated glycan moieties from the [M+Na]+ 
precursor ion. Monosaccharide symbols are as shown in Figure 2. (A) The 
fragmentation pattern of the parent ion m/z 2663 reveals the presence of two distinct 
isomeric glycans differing in the position of a terminal HexNAc residue. Fragment 
ions at m/z 660 and 905 are consistent with terminal blood group A, while the 
fragment ion at m/z 433 confirms the presence of blood group H epitope. In the lower 
structure representation, the terminal non-reducing GlcNAc residue could also be a 
bisecting GlcNAc. (B) Collisional activation of the m/z 3054 parent ion provides 
evidence for numerous isoforms as well as the presence of lactosaminic elongations 
(diagnostic fragment ions at m/z 1296, 1781 and 2142). The three core fucosylated 
structures that are shown are assigned as the major components based on fragment 
ion abundances. However, the antenna fragment ion at m/z 660 indicates the 
presence of other components carrying a fucosylated N-acetyl lactosamine antenna 
and therefore lacking core fucosylation (not represented). Taking into account 
different antennae and core fucosylation combinations, at least 12 different isoforms 
can be attributed to this single molecular ion.  
 
Figure 4. The VWF N-glycan repertoire contains sulphated oligosaccharides.  
Analyses of the permethylated VWF N-glycans in the negative ion mode afforded a 
number of [M-H]- molecular ions consistent with mono-sulphated complex type N-
glycans (m/z 2647, 2821, 3008, etc.; sulphate indicated by a S in a red circle). A 
related family of molecular ions lacking an 80 Da moiety is also detected (m/z 2567, 
2741, 2928 etc., indicated with a blue star). This series is assigned to in-source loss 
of sulphite from each of the sulphated glycans. 
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Figure 5. Glycoproteomic analyses of the N1515 glycosylation site (glycopeptide 
P4). 
MS and MS/MS spectra were obtained by analysis of a desialylated tryptic digest of 
VWF. (A) MS/MS analysis of parent ion m/z 3420 shows fragments resulting from the 
loss of antennae whose compositions are shown on the horizontal arrows (m/z 2832, 
2909 and 3055). Antennae fragment ions are observed in the low mass range (m/z 
204, 366 and 512) while mid-mass fragment ions provide evidence for the identity of 
the peptide and the glycan core (m/z 904, 921, 1004). The fucose is found on either 
the core GlcNAc (m/z 1270) or the antennae (m/z 512 and 1124). (B) The MALDI-
TOF profile of UEA-I bound desialylated P4 glycopeptide (see Table 2 for the 
sequence of the P4 peptide).  A remarkable variety of H-antigen containing N-
glycans are observed. (C) MS/MS analysis of the parent ion m/z 3859 shows the 
presence of several H antigens on a single glycan (m/z 512 and 2837), one being 
potentially presented on a lactosamine extension (m/z 2674).  
 
Figure 6. The VWF glycome and site-specificity. 
(A) Representation of the human VWF N-glycan structural features. This figure 
highlights the set of epitopes observed along this study, comprising ABH blood 
groups, LacNAc extensions, bisecting and terminal GlcNAc and sulphated sialylated 
LacNAc antennae. (B) The functional domains of VWF are shown together with 
information on binding partners, the ADAMTS13 cleavage site and the dimerization 
region. The N-glycosylation sites that have been characterised in this study are 
shown as red circles and the structures of the most abundant glycans at each site 
are shown in the annotations. X indicates N-glycosylation sites whose glycosylation 
has not yet been defined.  
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